Genetic correction using engineered nucleases for gene therapy applications.
about
Current and future alternative therapies for beta-thalassemia majorThe therapeutic potential of genome editing for β-thalassemiaCell-Penetrating Peptide as a Means of Directing the Differentiation of Induced-Pluripotent Stem CellsMinimizing off-Target Mutagenesis Risks Caused by Programmable NucleasesState-of-the-art human gene therapy: part I. Gene delivery technologiesA snapshot of gene therapy in Latin AmericaDystrophic epidermolysis bullosa: a reviewGenome Editing and Muscle Stem Cells as a Therapeutic Tool for Muscular Dystrophies.A CRISPR view of development.State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications.Induced pluripotent stem cells as a discovery tool for Alzheimer׳s disease.Use of the HPRT gene to study nuclease-induced DNA double-strand break repair.BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector.A novel system for correcting large-scale chromosomal aberrations: ring chromosome correction via reprogramming into induced pluripotent stem cell (iPSC).Potential therapeutic application of dendrimer/cyclodextrin conjugates with targeting ligands as advanced carriers for gene and oligonucleotide drugs.Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy.Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential.CRISPR/Cascade 9-Mediated Genome Editing-Challenges and Opportunities
P2860
Q26750906-640F622B-B5C2-4A9B-A57B-6F450F56BB83Q26766232-2ED6CCFB-D430-4348-A015-609372DAE3F8Q26777415-93F646E0-4A1A-4D13-AD98-5DA3289A6C7DQ26778992-0D068748-4DFC-419A-AEA8-7641EFFDB93BQ26825575-3883846A-4A8A-4F3D-945E-578C21C5DC4FQ26998837-C32C0822-1E1C-4028-ADCE-B47BA09FE4C4Q28084871-DF3D84B3-ED40-4826-A54A-30212BB04B77Q33729585-615B59B6-A8EB-40B1-B16C-2B0D7AA157C4Q34342877-BF506478-883F-46BF-B36C-2D3BE27BFB73Q34664690-57D4D2E4-CADC-4476-B64E-AE6A8A1E2208Q38605546-978F7118-EE86-4A7B-98B4-E78ED2309B10Q38831224-8682A19E-398A-4EAB-AC68-B015B378E9B8Q38843183-CE3F565F-7FBF-410C-947A-0289C682A173Q39018563-0FF86226-D61E-48DA-AA27-C8A7C01FB163Q39145487-2D16A6BF-5627-4F7F-AF6A-D04AED281770Q39368114-DF2FA397-5B7E-4BDA-AB2F-DD32CBD0AA89Q41873090-61A3A374-7B73-4386-9769-2C78F0C3B432Q44441472-D4CFA811-A55E-4088-8B13-61795CB31C2EQ57177058-1604687A-9519-420B-A043-C8D9277D49CA
P2860
Genetic correction using engineered nucleases for gene therapy applications.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Genetic correction using engineered nucleases for gene therapy applications.
@en
type
label
Genetic correction using engineered nucleases for gene therapy applications.
@en
prefLabel
Genetic correction using engineered nucleases for gene therapy applications.
@en
P2860
P356
P1476
Genetic correction using engineered nucleases for gene therapy applications.
@en
P2093
Hongmei Lisa Li
Takao Nakano
P2860
P356
10.1111/DGD.12107
P50
P577
2013-12-11T00:00:00Z